---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-26-000083"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2026-08-04T12:46:07+00:00"
generated_at: "2026-08-04T12:50:12.258549+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evolus expands Estyme HA gel rights to Canada, Australia, New Zealand; expects 2028 launch

## Summary
- Upfront payment of €920,000 plus up to €1.38 million upon regulatory approvals.
- Estyme complements Jeuveau/Nuceiva; combined neurotoxin & filler TAM ~$500M annually.
- Commercialization expected in 2028, subject to applicable regulatory approvals.
- Symatese responsible for development, manufacturing, and regulatory; Evolus pays mid-single digit royalty.
- Agreement expected to be accretive to Evolus' international gross margins.

## SEC filing metadata
- accession: 0001570562-26-000083
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2026-08-04T12:46:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056226000083/0001570562-26-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056226000083/eols-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-26-000083
- JSON: https://secwatch.observer/filing/0001570562-26-000083.json
- Plain text: https://secwatch.observer/filing/0001570562-26-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.